Bioconjugated liquid-like solid enhances characterization of solid tumor - chimeric antigen receptor T cell interactions
Source abstract
Abstract
Chimeric antigen receptor (CAR) T cell therapy has demonstrated remarkable success as an immunotherapy for hematological malignancies, and its potential for treating solid tumors is an active area of research. However, limited trafficking and mobility of T cells within the tumor microenvironment (TME) present challenges for CAR T cell therapy in solid tumors. To gain a better understanding of CAR T cell function in solid tumors, we subjected CD70-specific CAR T cells to a challenge by evaluating their immune trafficking and infiltration through a confined 3D microchannel network in a bio-conjugated liquid-like solid (LLS) medium. Our results demonstrated successful CAR T cell migration and anti-tumor activity against CD70-expressing glioblastoma and osteosarcoma tumors. Through comprehensive analysis of cytokines and chemokines, combined with in situ imaging, we elucidated that immune recruitment occurred via chemotaxis, and the effector-to-target ratio plays an important role in overall antitumor function. Furthermore, through single-cell collection and transcriptomic profiling, we identified differential gene expression among the immune subpopulations. Our findings provide valuable insights into the complex dynamics of CAR T cell function in solid tumors, informing future research and development in this promising cancer treatment approach. STATEMENT OF SIGNIFICANCE: The use of specialized immune cells named CAR T cells to combat cancers has demonstrated remarkable success against blood cancers. However, this success is not replicated in solid tumors, such as brain or bone cancers, mainly due to the physical barriers of these solid tumors. Currently, preclinical technologies do not allow for reliable evaluation of tumor-immune cell interactions. To better study these specialized CAR T cells, we have developed an innovative in vitro three-dimensional model that promises to dissect the interactions between tumors and CAR T cells at the single-cell level. Our findings provide valuable insights into the complex dynamics of CAR T cell function in solid tumors, informing future research and development in this promising cancer treatment approach.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: CAR-T cell therapy research · Nanowire Synthesis and Applications · Viral Infectious Diseases and Gene Expression in Insects
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (86)
Show source-provided references
1. A community effort to assess and improve drug sensitivity prediction algorithms10.1038/nbt.2877 ↗
2. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients10.1038/nature14320 ↗
3. CAR T cell locomotion in solid tumor microenvironment10.3390/cells11121974 ↗
4. Effects of immune checkpoint blockade on antigen-specific CD8+ T cells for use in adoptive cellular therapy10.1111/1348-0421.12967 ↗
5. Cancer statistics, 2022,” CA10.3322/caac.21708 ↗
6. FDA approval summary: tisagenlecleucel for treatment of patients with relapsed or refractory b-cell precursor acute lymphoblastic leukemia10.1158/1078-0432.CCR-18-2035 ↗
7. FDA approval summary: axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma10.1158/1078-0432.CCR-18-2743 ↗
8. Three-year follow-up of KTE-X19 in patients with relapsed/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 Study
9. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study10.1016/S0140-6736(20)31366-0 ↗
10. FDA approval summary: idecabtagene vicleucel for relapsed or refractory multiple myeloma10.1158/1078-0432.CCR-21-3803 ↗
11. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study10.1016/S0140-6736(21)00933-8 ↗
12. Chimeric antigen receptor T cells for sustained remissions in leukemia10.1056/NEJMoa1407222 ↗
13. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic, leukemia10.1126/scitranslmed.3008226 ↗
14. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia10.1056/NEJMoa1709866 ↗
15. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia10.1056/NEJMoa1709919 ↗
16. High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients10.1038/leu.2017.145 ↗
17. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas10.1038/s41586-022-04489-4 ↗
18. CRISPR-engineered T cells in patients with refractory cancer10.1126/science.aba7365 ↗
19. CAR-T cell therapy: current limitations and potential strategies10.1038/s41408-021-00459-7 ↗
20. T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies10.1182/blood-2010-04-278218 ↗
21. Expression of the immune regulation antigen CD70 in osteosarcoma10.1186/s12935-015-0181-5 ↗
22. Tumor associated CD70 expression is involved in promoting tumor migration and macrophage infiltration in GBM10.1002/ijc.30830 ↗
23. CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors10.1038/s41467-019-11869-4 ↗
24. CD70, a novel target of CAR T-cell therapy for gliomas10.1093/neuonc/nox116 ↗
25. CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity10.1182/blood.2020008221 ↗
26. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy10.1038/nri.2017.49 ↗
27. Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors10.1158/1078-0432.CCR-13-2627 ↗
28. CAR T cell locomotion in solid tumor microenvironment
29. Adoptive cell therapy in pediatric and young adult solid tumors: current status and future directions10.3389/fimmu.2022.846346 ↗
30. Mouse models for cancer research10.5732/cjc.011.10047 ↗
31. Genetically engineered mouse models in oncology research and cancer medicine10.15252/emmm.201606857 ↗
32. Modelling CAR-T therapy in humanized mice10.1016/j.ebiom.2019.01.029 ↗
33. Concise review: humanized models of tumor immunology in the 21st century: Convergence of cancer research and tissue engineering10.1002/stem.1978 ↗
34. Modeling human tumor-immune environments in vivo for the preclinical assessment of immunotherapies10.1007/s00262-021-02897-5 ↗
35. Matrigel: Basement membrane matrix with biological activity10.1016/j.semcancer.2005.05.004 ↗
36. Synthetic alternatives to Matrigel10.1038/s41578-020-0199-8 ↗
37. A practical guide to hydrogels for cell culture10.1038/nmeth.3839 ↗
38. Engineering T cells to enhance 3D migration through structurally and mechanically complex tumor microenvironments10.1038/s41467-021-22985-5 ↗
39. Evaluating CAR-T cell therapy in a hypoxic 3D tumor model
40. Microfluidic organs-on-chips10.1038/nbt.2989 ↗
41. A reproducible bioprinted 3D tumor model serves as a preselection tool for CAR T cell therapy optimization10.3389/fimmu.2021.689697 ↗
42. Liquid-like solids support cells in 3D10.1021/acsbiomaterials.6b00218 ↗
43. Is it time to start transitioning from 2D to 3D cell culture?10.3389/fmolb.2020.00033 ↗
44. Three-dimensional cell culture models for anticancer drug screening: worth the effort?10.1002/jcp.26052 ↗
45. Mechanisms of 3D cell migration10.1038/s41580-019-0172-9 ↗
46. Generation and characterization of ErbB2-CAR-engineered cytokine-induced killer cells for the treatment of high-risk soft tissue sarcoma in children10.18632/oncotarget.19821 ↗
47. 3D hanging spheroid plate for high-throughput CAR T cell cytotoxicity assay
48. A spheroid killing assay by CAR T cells
49. A simplified isotope release assay for cell-mediated cytotoxicity against anchorage dependent target cells10.1016/0022-1759(77)90163-6 ↗
50. NK-cell-dependent killing of colon carcinoma cells is mediated by natural cytotoxicity receptors (NCRs) and stimulated by parvovirus infection of target cells10.1186/1471-2407-13-367 ↗
51. Dynamic profiling of antitumor activity of CAR T cells using micropatterned tumor arrays10.1002/advs.201901829 ↗
52. The flow cytometric PKH-26 assay for the determination of T-cell mediated cytotoxic activity10.1016/S1046-2023(03)00123-3 ↗
53. Development and characterization of a novel luciferase based cytotoxicity assay10.1038/s41598-017-18606-1 ↗
54. A novel co-culture assay to assess anti-tumor CD8+ T cell cytotoxicity via luminescence and multicolor flow cytometry
55. ROR1-CAR T cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models10.1172/jci.insight.126345 ↗
56. 3D model for CAR -mediated cytotoxicity using patient-derived colorectal cancer organoids10.15252/embj.2018100928 ↗
57. Migration of tumor cells in 3D matrices is governed by matrix stiffness along with cell-matrix adhesion and proteolysis10.1073/pnas.0604460103 ↗
58. A cancer invasion model combined with cancer-associated fibroblasts aggregates incorporating gelatin hydrogel microspheres containing a p53 inhibitor10.1089/ten.tec.2019.0189 ↗
59. Collagen density regulates the activity of tumor-infiltrating T cells10.1186/s40425-019-0556-6 ↗
60. Stimuli-responsive microgels and microgel-based systems: advances in the exploitation of microgel colloidal properties and their interfacial activity10.3390/polym10040418 ↗
61. Functional microgels and microgel systems10.1021/acs.accounts.6b00544 ↗
62. 3D in vitro platform for cell and explant culture in liquid-like solids10.3390/cells11060967 ↗
63. Bioconjugation of COL1 protein on liquid-like solid surfaces to study tumor invasion dynamics10.1116/6.0002083 ↗
64. In situ 3D spatiotemporal measurement of soluble biomarkers in spheroid culture10.1007/s44164-022-00037-6 ↗
65. UALCAN: an update to the integrated cancer data analysis platform10.1016/j.neo.2022.01.001 ↗
66. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses10.1016/j.neo.2017.05.002 ↗
67. Preclinical evaluation of chimeric antigen receptors targeting CD70-expressing cancers10.1158/1078-0432.CCR-16-1421 ↗
68. Cellpose: a generalist algorithm for cellular segmentation10.1038/s41592-020-01018-x ↗
69. Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression10.1084/jem.20192203 ↗
70. CXCR3/CXCR3 ligand biological axis impairs RENCA tumor growth by a mechanism of immunoangiostasis10.4049/jimmunol.176.3.1456 ↗
71. Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints10.1038/ncomms8458 ↗
72. CCR2 is required for CD8-induced graft-versus-host disease10.1182/blood-2005-05-1860 ↗
73. CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation – A target for novel cancer therapy10.1016/j.ctrv.2017.11.007 ↗
74. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis10.1038/nature10138 ↗
75. Generation and biobanking of patient-derived glioblastoma organoids and their application in CAR T cell testing10.1038/s41596-020-0402-9 ↗
76. Single-cell imaging of CAR T cell activity in vivo reveals extensive functional and anatomical heterogeneity10.1084/jem.20182375 ↗
77. CART math — a mathematical model of CAR-T immunotherapy in preclinical studies of hematological cancers10.3390/cancers13122941 ↗
78. Mathematical deconvolution of CAR T-cell proliferation and exhaustion from real-time killing assay data10.1098/rsif.2019.0734 ↗
79. A validated mathematical model of cell-mediated immune response to tumor growth10.1158/0008-5472.CAN-05-0564 ↗
80. CAR T cells in solid tumors: challenges and opportunities10.1186/s13287-020-02128-1 ↗
81. CD27 is required for generation and long-term maintenance of T cell immunity10.1038/80877 ↗
82. CD19 and CD70 dual-target chimeric antigen receptor T-cell therapy for the treatment of relapsed and refractory primary central nervous system diffuse large B-cell lymphoma10.3389/fonc.2019.01350 ↗
83. Impact of stress on cancer metastasis10.2217/fon.10.142 ↗
84. Hyperprogression and immunotherapy: fact, fiction, or alternative fact?10.1016/j.trecan.2020.01.005 ↗
85. Immune escape after adoptive T-cell therapy for malignant gliomas10.1158/1078-0432.CCR-20-1065 ↗
86. Higher doses of tisagenlecleucel associate with improved outcomes: a report from the pediatric real-world CAR consortium